Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes

Enrolling by invitation

Conditions studied: Severe Asthma

In brief

To evaluate the relationship between starting tezepelumab treatment followed by tapering of inhaled corticosteroid (ICS) and ICS dose, metabolic outcomes, asthma control and exacerbation rate in a real world setting

Key facts

Study ID

NCT07713498

Run by

Franciscus Gasthuis

People needed

61

Starts

2026-05-01

Expected to finish

2027-10-01

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18
• Patient diagnosed with severe asthma according to the GINA guidelines
• Written informed consent (AVG).
• Eligibility and willingness to present during an asthma exacerbation at the Franciscus hospital.
• Patient has received/or has been planned for at least one dose of tezepelumab
• Sufficient understanding of the Dutch or English language

You may not qualify if…

• Other underlying inflammatory or auto-immune diseases that require OCS treatment, such as rheumatologic disease, IBD etc.
• Pregnancy, because of the possible altered immunological status.
• Participation in an interventional study that interferes with this study.

Where it is running

• Franciscus Gasthuis & Vlietland — Rotterdam, South Holland, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.